The objective of this study was to confirm if two formulations of nimesulide tablets are
Test product was Eskaflam® (Nimesulide 100 mg tablets; GlaxoSmithKline) and reference product
Mesulid® (Nimesulide 100 mg tablets; Syntex for Productos Roche). The single dosage was one
The study was prospective, open-label, randomized, crossover, single dose, with 02
treatments, 02 sequences and 02 periods, under fasting conditions.
The population was composed of 28 healthy volunteers, both genders, adults between 18-40
The comparative bioavailability of the two formulations was evaluated based in statistical
comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations